Silverback Therapeutics, Inc.
NASDAQ: SBTX0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Peter A. Thompson
- Employees
- 90
- Headquarters
- Seattle, United States
- IPO year
- 2020
- Market cap
- $550.4M
- Website
- https://www.silverbacktx.com
Loading SBTX…
Loading profile data…Frequently asked questions about SBTX
What does Silverback Therapeutics, Inc. (SBTX) do?
Silverback Therapeutics, Inc. operates as a biotechnology firm dedicated to devising tissue-specific drug candidates aimed at addressing chronic viral infections, various cancers, and other significant medical conditions. Among its pipeline, SBT8230 stands out as a treatment for chronic hepatitis B virus, working by stimulating an antiviral immu...
Where does SBTX trade?
Silverback Therapeutics, Inc. (SBTX) trades on the NASDAQ Global Market.
What sector is SBTX in?
Silverback Therapeutics, Inc. (SBTX) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Silverback Therapeutics, Inc.?
Peter A. Thompson is the chief executive officer of Silverback Therapeutics, Inc. (SBTX).
Where is Silverback Therapeutics, Inc. headquartered?
Silverback Therapeutics, Inc. is headquartered in United States.
Does SBTX pay a dividend?
Silverback Therapeutics, Inc. (SBTX) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did SBTX go public?
Silverback Therapeutics, Inc. (SBTX) completed its initial public offering in 2020.